View in EDS

SA25 Burden of Administration: Belantamab Mafodotin (Belamaf) Combinations vs Isatuximab (Isa) + Carfilzomib (K) + Dexamethasone (d), Daratumumab (D) + K + d, and K + d in Relapsed/Refractory Multiple Myeloma (RRMM).

Saved in:

Bibliographic Details
Title:	SA25 Burden of Administration: Belantamab Mafodotin (Belamaf) Combinations vs Isatuximab (Isa) + Carfilzomib (K) + Dexamethasone (d), Daratumumab (D) + K + d, and K + d in Relapsed/Refractory Multiple Myeloma (RRMM).
Authors:	SAMYSHKIN, Yevgeniy¹ (AUTHOR), Purser, Molly² (AUTHOR), Dlotko, Ewa³ (AUTHOR), Macleod, Paul³ (AUTHOR), Breslin, Katie³ (AUTHOR), Boytsov, Natalie² (AUTHOR), McNamara, Simon⁴ (AUTHOR), Sapra, Sandhya² (AUTHOR), Suvannasankha, Attaya⁵ (AUTHOR)
Source:	Value in Health. 2025 Supplement 1, Vol. 28 Issue 6, pS399-S399. 1p.
Database:	Academic Search Ultimate

Description
ISSN:	10983015
DOI:	10.1016/j.jval.2025.04.1780